IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.

By M. Ahmadzadeh, S. Rosenberg. Blood, 2006

658 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. (2015, methodology): “3- g/kg per day IL-15 infusions in contrast to the three- to five-fold increases observed with high-dose IL-2 administration.(33-36) We observed marked elevations in IL-6, IL-8, and IFN- as well as increases in IL-10, tumor necrosis factor , and IL-1 that also occurred within 2 to 4 hours after rhIL”
Regulatory T cells in cancer. (2006, background): “Similarly, in patients with melanoma or renal cell carcinoma (RCC) the frequency of fully functional Treg cells was significantly increased after IL2 treatment, which was also accompanied by an increase of FOXP3 demonstrating that administration of high dose IL2 increases the frequency of circulatin”